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Abstract: Visceral leishmaniasis (VL) or kala-azar is a worldwide disseminated intracellular
infection caused by the hemoflagellate protozoan parasites Leishmania donovani.
Chemotherapeutic scenario presents a deplorable picture and demands an urgent search for
a new and safe anti-VL drugs, preferably active by oral route. In search of new an-
tileishmanial agents, a total of 16 compounds belonging to the anilino-(substituted pnenyl)-
acetonitrile class were tested in-vitro in promastigote/macrophase-amastigote systems and
in-vivo in L. donovani/hamster model for their antileishmanial activity.. Compound 3,
anilino-(2-bromophenyl)-acetonitrile, exhibited most promising activity both in-vitro at a con-
centration of 100μg/ml (82.33% and 94.36% in promastigote and macrophase-amastigote
systems respectively) and in-vivo at a dose of 50 mg/kg for 5 days (82.12% and 80% by i.p.
and p.o. routes respectively), hence this compound was investigated in detail. To maximize
its bioavailability, dissolution profile, absorption, the compound was also tested in-vivo as its
soluble form. But no enhancement in activity was observed. From the results of different
parameters for example ED50 and LD50 etc. compound 3 appears to be a potent orally ef-
fective compound which could further be investigated to establish its potential as a candi-
date molecule of antileishmanial therapy.
Key words: Kala-azar, Visceral Leishmaniasis, Chemotherapy, Anti-leishmanials, Leishmania
donovani, Hamster, In vivo, In vitro, Formulation
INTRODUCTION
Visceral leishmaniasis (VL) or kala-azar, a disease affecting 61 out of the 88 countries
infected with leishmaniasis worldwide (Anon, 1996) is caused by the kinetoplastid protozoan
parasites belonging to the Leishmania donovani complex. The global number of infected in-
dividuals cannot be determined with accuracy, but according to WHO estimates there are at
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least 3-5 million clinical cases among the 12 million infected individuals from a total popula-
tion of about 350 million living in endemic areas (Anon, 1998). 1.5 million new cases are
reported each year, out of which 500,000 are estimated to be suffering from VL.
Bihar is the highly infected state in India. But the disease has spread to newer areas
also (Thakur et al, 1993, Jha et al, 1998). Epidemics have been seen in eastern Uttar
Pradesh, West Bengal (Gupta et al, 1997, Anon, 1999a, Kumar et al, 1999) and sporadic
cases have been reported from different parts of the country, where kala-azar was never seen
before (Jacob and Kalra, 1951, Gajwani et al, 1967, Gupta and Bhatia, 1975). Growing an-
timony resistance over last two decades has made treatment extremely difficult in North Bi-
har, which has more than 90% of country's VL cases (Anon, 1999a). Currently the first line
drug Sodium Antimony Gluconate is able to cure only 35-50% patients (Jha et al, 1998). Use
of second line drug pentamidine isethionate has largely been abandoned because of its toxic
manifestations and declining efficacy. Thus, in these areas amphotericin B remains the only
drug that can be used. Although it cures >97% cases, infusion related adverse effects are
commonand occasionally serious toxicity like myocardial disorders or death can occur (Sun-
dar et al, 1997). The results of clinical trials showed that a single dose of liposomal am-
photoericin B and aminoglycoside aminosidine are capable to cure kala-azar patients and may
replace antimony therapy as the first line drug (Sundar et al, 1997, 1998). Alkyl phospholipid
compound miltefosine (Sundar et al, 1999) is the first effective oral compound for VL and is
likely to be marketed soon. Moreover in the face of new challenges of drug resistance,
treatment failures, occurrence of relapses after therapy (Thakur et al, 1993, 1994, 1998;
Sundar et al, 1998; Jha et al, 1995, 1998) and convergence of HIV related VL (Alvar et al
1996; Russo et al, 1996; Anon, 1999b), there is an urgent need to search for new and better
alternative of Leishmania chemotherapy. In addition to monotherapy, efforts to develop
combination chemotherapy are also warranted if the menace of drug resistance is to be con-
tained.
In this study, we report the preliminary findings, which demonstrate promising anti-
leishmanial activity in newly synthesized anilino-(2-bromophenyl)-acetonitrile (3) and their
analogues by the oral route.
MATERIALS AND METHODS
Parasite:
The WHO reference strain of Leishmania donovani (Man/IN/80/Dd8) obtained from Im-
perial College, London (U.K) in 1979 has been maintained since then in this laboratory in
vitro as promastigotes in NNN medium, and as amastigotes in golden hamsters.
Animal:
Male golden hamsters (Mesocricetus auratus) weighing 45-50 g and bread in the Na-
tional Animal Laboratory Centre housed in CDRI, Lucknow, served as the experimental host.
They were maintained in temperature regulated rooms provided with standard rodent pellet
diet (Nav Maharashtra Chakan Oil Mills, Nav Maharashtra House, Pune, Maharashtra, India)
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and water ad libitum.
Compound:
Fig. 1 shows the structures of the compounds beloging to anilino-(phenyl)-acetonitriles.
A total of 16 compounds belonging to this class were primarily evaluated both in-vitro and
in-vivo (i.p.). Most promising compound 3 was evaluated in detail.
For in-vitro evaluations the compounds were dissolved in ethyl alcohol to give 1% so-
lutions. The desired concentrations were prepared by serially diluting the alcoholic solution
with complete medium.
For in-vivo evaluations the required concentration of each compound was prepared by
triturating the compounds in 100 jA of Tween-80 and finally suspending it in desired volumes













































































































1. In vitro screening:
Antipromastigote activity (or growth):
To assess the inhibition of promastigote growth, 1x105 promastigotes at stationary
growth phase were cultured in triplicate in 24 well culture plates (Tarson, India) at 26°C in
RPMI-1640 medium+ 10% PCS containing the varying concentrations (100, 50 and 25 p/ml of




The technique of Neal and Croft (1984) as standardized by Bhatnagar et al. (1989) was
adopted to assess the anti-leishmanial activity. Briefly, peritoneal macrophages obtained from
normal BALB/c mice by lavage with cold RPMI-1640 medium (Sigma) were plated in 8-
chamber "Lab-Tek" slides (Nunc, Naperville, USA) as 2xl05 cells per well and left to adhere
for 24 hrs at 37°C in C02 incubator. The non-adherent cells were removed by washing with
medium and the cell monolayers were infected with promastigotes suspended in RPMI 1640
medium + 10% PCS with the cell: parasite ratio being 1:10. Incubation was carried out for
another 24 hours and the infected cells were treated with different concentrations (100, 50
and 25 //g/ml) of the test compounds 3 in complete RPMI medium with a further incubation
of 48 hours. A second change of the compound in the same concentration was given followed
by incubation of another 48 hours. Finally, the cell monolayers were stained with 5% Giemsa
for 45 minutes and at least 100 infected macrophages per sample were counted under an
optical microscope. Efficacy was expressed as the percent inhibition of amastigote multipli-




Where PI is percent inhibition of amastigote multiplication, AT is actual number of
amastigotes/100 macrophage cells in treated groups and AC is actual number of
amastigotes/100 macrophage cells in untreated control groups.
2. In vitro screening:
The method of Beveridge (1963) as modified by Bhatnagar et al. (1989) was employed.
Briefly, intracardially infected hamsters with 5-15 amastigotes per 100 speen cell nuclei, as
assessed between day 20-25 post infection (p.i.) by spleen biopsy, were used for chemother-
apeutic trials. The infected animals were randomized into several groups on the basis of their
parasitic burdens. Drug treatment was continued for 5 consecutive days in the mentioned
concentrations (50, 25, 12.5, 6.25 and 3.12 mg/kg i.p and P.O.). Post-treated biopsy was done
on day 7 of the last drug administration and amastigote counts were assessed by Giemsa





Where PI is percent inhibition of amastigote multiplication, ANAT is actual number of
amastigotes in treated animals, INAT is initial number of amastigotes in treated animals and
TIUC is times increase of parasites in untreated control animals. This procedure was adopted
in all the experiments except otherwise mentioned.
Detailed investigations of Compound 3
Efficacy by different routes of administration:
The test compound 3 was administered via oral (P.O.), intraperitoneal (i.p.) intramuscu-
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lar (i.m.) routes at the effective dose regimen of 50 mg/kg x 5 days. The efficacy was calcu-
lated and expressed as the percent inhibition of parasite multiplication by the method men-
tioned above.
Determination of effective dose 50% (ED50):
On the basis of results obtained above, a number of descending doses of the test
compound 3 (viz. 50, 25, 12.5, 6.25 & 3.12 mg/kg x 5 days by i.p. and p.o. routes) were
evaluated to facilitate the statistical determination of ED50 values that were calculated on the
basis of percent inhibition in amastigote multiplication on day 7 p.t. by the method of Basil
(1963). Stibanate (Sodium stibogluconate) was simultaneously used at a dose of 20 mg/kg x 5
days i.p. as reference drug.
Determination of lethal dose 50% (LD50):
The acute toxicity tests were carried out in healthy mice (20-25 g) to determine the
lethal dose that will kill 50% of the animals by the method described by Bushby (1963).
Briefly, adult male mice were administered with sighting doses (viz. 464, 1000, 2150, 4640
mg/kg x 1 day) of the test compound by i.p. and p.o. routes. Six animals were employed at
each dose level. Control (untreated) animals received similar treatment of normal saline by
the similar routes. The animals were closely observed for the next 24 hours for any signs of
adverse effects and mortality, if any, occurring during this period. LD50 was determined
statistically from the data obtained.
Assessment of activity in early infection:
A group of infected hamsters (IxlO7 amastigotes/hamster) were divided randomly into 3
groups of 4 animals each. Treatment with the test compound (50mg/kgx5d) was initiated on
day 5 p.i. A group of infected hamsters given similar treatment of normal saline served as
control. All the animals were biopsied on day 25 p.i. and the parasitic burdens of treated and
untreated groups were compared using the following formula.
Nr-Ntpl=m:m
Nc
Where PI is percent inhibition, Nc is number of amastigotes per 100 cell nuclei in
control group and Nt is number of amastigotes per cell nuclei in treated group.
Evaluation of efficacy using different treatment regimens:
The test compounds were evaluated in infected hamsters in treatment regimens of 25
mg/kg x 10 days (O.D.), 25mg/kg x 10 days (B.D.), 50mg/kg x 5 days (B.D.), 50mg/kg x 10 days
(B.D.) and 50mg/kg x 30 days (B.D.) by the method described under "In-vivo screening". Ef-
ficacy was determined and expressed as the percent inhibition of amastigote multiplication on
day 7 p.t. using the formula mentioned earlier.
Evaluation of efficacy using soluble preparation:
The soluble preparation of compound 3 was evaluated in hamsters by p.o. (50 mg/kg x
5 days) and i.p. (50, 25, 12.5, 6.25 & 3.12 mg/kg x 5 days) routes of administration. For the
preparation of soluble form 10.0g of crystalline HPLC pure 3, was dissolved in 50ml of
propylene glycol (Merck India Ltd.) over a boliling water bath for 10 minutes. The clear
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solution thus obtained was cooled to room temperature and diluted further to desired con-
centrations using propylene glycol. The solutions were sterilized by filtration through 0.2 pm
membranefilter before administration to the animals.
Statistical analysis:





Out of a total of 16 compounds belonging to anilino-(phenyl)-acetonitriles, only com-
pounds 3 {anilino-(2-bromophenyl)-acetonitrile} inhibited multiplication of the axenically
growing promastigotes to the tune of 82.33%, 75.80% and 57.45% at concentrations of 100,
50 and 25 //g/ml respectively. Rest of the compounds didn't show significant activity (data
not shown in tables).
Antiamastigote activity:
The compound 3 was highly effective against intracellular amastigotes cultured in
macrophages in vitro exhibiting 94.36%, 64.40% and 52.5% inhibition of parasite multiplica-
tion at the concentrations of 100, 50 and 25 ^g/ml respectively whereas rest of the com-
pounds failed to show any remarkable activity (data not shown in tables).
In vivo screening
Out of 16 compounds screened only compound 3 exhibited 82.12% activity by i.p. route
at the dose of 50 mg/kg x 5 days. Other analogues showed poor to moderate activity (Table-1)
Table-1. Preliminary in vivo testing of Anilino-(phenyl)-acetonitriles in the L.donovani
hamster model
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Detailed investigations of Compound 3
Efficacy by different routes:
The compound 3 was found to be very effective by both i.p. and p.o. routes of ad-
ministration exhibiting 82.12% and 80% inhibition of amastigote multiplication respectively.
However, the efficacy was greatly reduced (43.46%) when i.m. route was employed.
Effective dose 50% (ED50):
The compound 3 exhibited a maximum efficacy of 82.12% and 80.00% at the dose
regimen of 50mg/kg x 5 d by i.p. and p.o. routes respectively and at lower dose regimens a
dose-dependent response was evident. ED50 values were found to be 9.632 mg/kg x 5 d and
25.26 mg/kg x 5 d by i.p. and p.o. routes respectively (Table-2).
Table-2. Efficacy of compound 3 against L. donovani in golden hamster
SI. Drug Dose Route of Percent Number of Effective dose
No- (mg/kg x d) admini- inhibition animals/ 50% (ED50)








































9 .632mg/kg x 5 d
(Feducial limit
7.792-ll.906)
25.263mg/kg x 5 d
(Feducial limit
22.692-28.124)
NI=No inhibition in amastigote number compared to controls
Lethal dose 50% (LD50):
The compound 3 was well tolerated by the mice up to a dose of 1000mg/kg x 1 d when
administered by the i.p. route, however, further incremental doses led to mortality (LD50 2271
mg/kgxl) (Table-3). When given by p.o. route, the test compound was very safe exhibiting
LD50 of>5000mg/kg x 1.
Table-3. Acute toxicity test of compound 92/187 in healthy mice (24 hrs observation period)



























2271mg/kg x 1 d
>5000mg/kg x I d
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Efficacy in early stage of infection:
Trials on efficacy of the compound 3 in early infection showed that it was more ef-
fective against the hepatic parasites (76.36% inhibition in amastigote multiplication) as com-
pared to the splenic parasites (67.50% inhibition in amastigote multiplication).
Efficacy at different treatment regimens:
From the efficacy data (Table-4) it is evident that the test compound 3 was most ef-
fective at the dose of 25mg/kg x 5 days. Any increase in the drug amount (from 25mg/kg x 10
days, B.D. to 50mg/kg x 5 days, B.D.) or in the duration of treatment (from 5 to 10 days)
resulted in decreased efficacy. Even administration of 50mg/kg of the compound for 10 and 30
days resulted in a remarkable loss of activity (39.93% and 19.50% respectively). Very high
concentrations of the drug (100 & 200 mg/kg), given over a period of 5 days, was not very
effective (59.19% and 34.14% inhibition in amastigote counts) emphasizing the fact that a
total of 250 mg given over a period of 5 days in any regimen was most effective in curbing
parasite multiplication.
Table-4. Efficacy of compound 92/187 at different treatment regimens by oral route






































*Data are means±standard deviation (n=8)
**No. of replicates
Efficacy of soluble form:
Table-5 shows that the soluble form of the test compound 3 was very effective orally at
50mg/kg x 5 days dose level (75.6% inhibition of parasite multiplication), but it appeared to be
toxic to the animals, which experienced intense irritation and restlessness during the treat
Table-5. In vivo efficacy of soluble preparation of compound 3
Sl.No. Dose Route Percent Effective dose No. of animals
Mg/Kg Inhibition 50% (ED50) treated/No, of



































ment pepriod. When tested by i.p. route the efficacy (75.59%) was consistent with that by
oral route at the effective dose of 50mg/kg x 5 d and the survival rate was slightly improved,
however irritation and restlessness persisted. Lower doses showed dose dependent efficacy.
DISCUSSION
Antileishmanial therapy is advancing by leaps and bounds with liposomal preparation
and immunotherapy being exploited to serve the patients better. However, there is still an
eagerness to explore new leads in search for a better, safe and more easily administrable
drug(s) to tackle this dreaded disease.
With the above in view a total of 16 of new synthetic compounds belonging to the class
of substituted arylacetonitriles, were evaluated in-vitro and in-vivo for their antileishmanial
activity. Experiments revealed that substituents at the aryl rings, either on the aniline part or
on the phenyl ring affected the efficacy of the compound as the unsubstituted compound 1
exhibited minimum efficacy (Table-1). In general the compounds with the substitution of the
phenyl ring exhibited better anti-leishmanial profile than the compounds with the substitution
on the aniline component. On the other hand the compounds with the substitution both on the
aniline ring and on phenyl ring showed negligible anti-leishmanial activity. In phenyl ring, the
substitution with halogens produced more pronounced activity in comparison to other sub-
stituents. Among the halo substituents, the compound 3 with 2-bromo substitution in phenyl
ring caused a marked increase in anti-leishmanial activity than other halo substituents at
position-2 (compound 2) or position-3 (compound 4, 5, 6) or position-4 (compound 7). It was
clearly evident that in case of chloro subsitution, o-Cl derivative (compound 2) showed greater
inhibition than m-Cl (compound 4) or p-Cl (compound 7) and in case of 4,5-dihalo substituted
derivatives (compound 8) moderate activity was observed. In case of fluro substitution, the
meta substituted derivative 6 showed the promising response but it was not better than 2-
bromo derivative 3.
Since compound 3 showed maximumefficacy, detailed investigations were carried out
with only this compound in order to determine its potential as an effective antileishmanial
agent.
The test compound being highly crystalline in nature had poor dissolution and absorp-
tion properties, therefore to maximise its bioavailability, dissolution profile and subsequently
its absorption through cellular membranes, its soluble form was tested in-vivo. But there was
no enhancement in activity with this form. Instead soluble form exhibited toxic manifestations
like intense irritation and restlessness during the treatment period probably due to quick
absorption of the drug.
The route of drug administration is a very important criterion, which greatly affects
efficacy of a drug. Therefore the test compound 3 was evaluated simultaneously by p.o., i.p,
and i.m. routes. It exhibited maximumactivity both by i.p as well as with oral routes. The
poor efficacy was observed by i.m. route, which may be attributed to the fact that the
compound on administration in the form of a suspension may form a depo, which may pre-
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vent its adequate distribution and bioavailability to the target organs.
Further trials on efficacy showed that the compound 3 was more effective against liver
parasites (76.36% inhibition) as compared to splenic parasites (67.50% inhibition) during the
early stages of infection. In patent infections a total of 250mg/kg given over a period of 5 days
was most effective in curbing parasite multiplication. It was surprising to note that on in-
creasing the dose and/or duration of the treatment the activity of the compound 3 decreases.
We are investigating this behavior of the compound in detail.
The compound 3 was also found to be extremely safe to experimental mice even at
very high dosages with LD50 values being 2271 and>5000mg/kg x 1 d by i.p. and p.o. routes
respectively.
The above studies have helped us in indentifying a new lead that could be exploited as
a potential orally active antileishmanial agent. Although, the test compound 3 showed
promising activity it could not exceed the efficacy of the standard reference drug stibanate
(Table-2). However due to its merits of easy synthetic procedure, efficacy by oral route and
very high LD50, this molecule could further be investigated to establish its potential as a
candidate molecule for antileishmanial therapy.
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